Exagen reports Q4 EPS (20c), consensus (24c)

Reports Q4 revenue $13.6M, consensus $13.85M. “The execution of our operational turnaround continued in earnest during 2024, which is reflected in our transformative financial results and is a testament to the strength of our team and strategy,” said John Aballi, President and CEO. “We have continued to grow profitable revenue and expand gross margins while significantly reducing operating expenses and cash burn. Additionally, the successful launch of our new AVISE CTD biomarkers this past January is a significant milestone in our commitment to improving patient care. With these accomplishments, Exagen (XGN) is better positioned for success, and I am excited about the momentum we carry into 2025 as we drive towards profitability.”